Table 1.
Effect of Donor Cell Treatment with Different Concentrations of TSA, NaB, and AzC on Developmental Competence and Quality of the SCNT-Derived Embryo
| |
|
|
|
Embryo development (%) |
Blastocyst quality |
||||
|---|---|---|---|---|---|---|---|---|---|
| No. replicates | Activated oocytes (n) | Cleavage | Blastocyst | Blastocyst (n) | ICM | TCN | ICM/TCN (%) | ||
| Untreated | 9 | 403 | 356 (94.7±1.4) ab | 102 (28.7±1.8) a | 15 | 31.1±1.9 a | 121.1±3.9a | 25.7±1.5 a | |
| 0.03 | 4 | 116 | 98 (83.9±5.6) ab | 29 (29.6±1.2) ab | 10 | 37.3±2.9 ab | 131.4±6.3 ab | 28.2±1.6 ab | |
| TSA (μM) | 0.08 | 4 | 141 | 124 (88.0±3.1) ab | 47 (37.9±1.8) bc | 9 | 44.9±3.3 b | 134.8±6.4 ab | 33.1±1.4 bc |
| 1.0 | 3 | 112 | 93 (89.4±4.7) ab | 42 (45.2±0.8) c | 12 | 57.1±2.9 c | 146.1±3.9 b | 38.9±1.4 c | |
| 0.5 | 3 | 124 | 102 (89.5±1.8) ab | 28 (27.4±1.3) a | 9 | 37.2±3.7 ab | 118.8±5.7 a | 30.9±2.0 a | |
| NaB (mM) | 1.0 | 5 | 161 | 146 (93.6±2.2) ab | 58 (39.7±2.1) b | 10 | 43.3±2.7 b | 140.1±5.7 b | 30.8±1.3 a |
| 2.0 | 3 | 110 | 95 (95.9±2.1) ab | 46 (46.5±0.8) b | 12 | 54.3±2.8 c | 146.6±5.1 b | 36.9±1.0 b | |
| 0.01 | 5 | 175 | 154 (97.5±0.7) b | 36 (23.3±1.3) a | 8 | 37.8±3.3 a | 121.5±7.0 a | 30.7±1.1 a | |
| AzC (μM) | 0.08 | 3 | 104 | 93 (97.9±2.1) b | 19 (20.4±3.9) a | 7 | 24.4±2.2 ab | 105.6±6.9 ab | 22.9±0.8 ab |
| 0.3 | 4 | 157 | 133 (89.3±0.9) a | 2 (1.5±1.5) b | 2 | 16.5±1.5 b | 83.0±6.0 b | 19.9±0.4 b | |
Within each column, values with at least one different letter are significantly different at p<0.05.
SCNT, somatic cell nuclear transfer; TSA, trichostatin A; AzC, 5-Aza-2′ -deoxycytidine; NaB, sodium butyrate.